Stellar Biotechnologies, Inc. (NASDAQ:SBOT) rose +68.48% during previous trade. Maxim Group issued rating on the stock of Stellar Biotechnologies, Inc. (NASDAQ:SBOT) in a research note issued to investors on Dec-02-16, the stock received “Reiterated” rating from Buy from $7 to $4. Additionally Maxim Group issued their verdict on the stock of the company, on record date of Aug-01-16 the stock was “Reiterated” from Buy from $17 to $7.
Stellar Biotechnologies, Inc. (SBOT) uncovered financial results for the three months ended December 31, 2018 and provided an update on its business.
Stellar President and Chief Executive Officer Frank R. Oakes said that the company continues to execute on its strategy to unlock new opportunities for growth. “During the quarter, we continued to advance our growth strategy and took steps designed to increase the flexibility and efficiency of Stellar’s aquaculture production systems.”
The company ended its first fiscal quarter with approximately $9 million in cash and short-term investments. “Our expenditures were largely in line with our expectations and historical results,” said Stellar Chief Financial Officer Kathi Niffenegger. “We believe it’s prudent to be vigilant with our working capital and management continues to take steps intended to conserve cash.”
Financial Results for the Three Months Ended December 31, 2018
Total revenues increased by $0.03 million to $0.05 million for the three months ended December 31, 2018 compared to $0.02 million for the same period last year primarily due to increased sales of higher value, clinical-grade KLH products.
Total operating expenses increased by $0.05 million to $1.46 million for the three months ended December 31, 2018 compared $1.41 million for the same period last year:
- Cost of sales increased by $0.03 million to $0.03 million for the three months ended December 31, 2018 compared to less than $0.01 million for the same period last year primarily due to increased product sales.
- Cost of aquaculture decreased by $0.02 million to $0.08 million for the three months ended December 31, 2018 compared to $0.10 million for the same period last year primarily due to a decrease in contracted quality testing services.
- Research and development expenses decreased by $0.16 million to $0.47 million for the three months ended December 31, 2018 compared to $0.63 million for the same period last year. The decrease was primarily due to a decrease in contracted research services and materials.
- General and administrative expenses increased by $0.20 million to $0.88 million for the three months ended December 31, 2018 compared to $0.68 million for the same period last year primarily due to increased legal and professional fees and public company expenses.
For the first quarter of fiscal year 2019, Stellar reported a net loss of $1.41 million, or $0.26 per basic share, compared to a net loss of $1.40 million, or $ 0.93 per basic share, for the first quarter of the prior fiscal year.
At December 31, 2018, the company had working capital of $8.87 million. Cash, cash equivalents and short-term investments totaled $8.96 million.
Stellar Biotechnologies, Inc. (NASDAQ:SBOT)’s highest estimates of price target are $2.00 and low forecast is $2.00 based on the opinion of 1 analysts. The price target estimates represents a standard deviation of 2.00. However brokerage recommendations suggests an ABR of N/A based on calls of N/A experts, where N/A brokers polls the stock a Strong Buy, N/A suggest the stock a Buy, N/A suggest Hold, N/A are rating the stock as Sell while N/A as Strong Sell.
The stock exchanged hands 25,742,085 shares versus average trading capacity of 569.70K shares, while its shares’ total market worth is $4.93M along with 2.99M outstanding shares. Stellar Biotechnologies, Inc. shares were trading -74.38% below from the 52-week high price mark of $7.63 and +68.48% above from the 52-week price bottom of $0.75. However the company observed 52 week high price on Feb 6, 2019 and witnessed 52 week low price on Feb 11, 2019. The company’s price sits -17.38% below from its 50-day moving average of $1.13 and -53.51% away from the stock’s 200-day moving average which is $1.22. SBOT’s price to sales ratio for trailing twelve month stands at 49.33, whereas its price to book ratio for most recent quarter sits at 0.52. However the company’s price to cash per share for most recent quarter stands at 1.30. Its price to free cash flow for trailing twelve months is N/A.
Stellar Biotechnologies, Inc. (NASDAQ:SBOT) performance over the past one year plunged -78.95% whereas its year to date (YTD) performance indicated a bearish trend of -70.90%. During the last six months the stock slipped -74.10%. Quarterly performance of the company shows declining momentum of -70.90% while its last one month trend is negative with -21.80%. Stock’s weekly performance expressed down trend of -9.34%.